Anders Dahm

Summary

Affiliation: University of Oslo
Country: Norway

Publications

  1. ncbi Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis
    Anders Dahm
    Department of Hematology, Ulleval University Hospital, Oslo, Norway
    Blood 101:4387-92. 2003
  2. ncbi Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state
    Anders Dahm
    Department of Haematology, Ulleval University Hospital, Oslo, Norway
    Br J Haematol 132:333-8. 2006
  3. doi Mechanisms of thrombosis related to hormone therapy
    Per Morten Sandset
    Oslo University Hospital at Ullevål, Department of Hematology, Oslo, Norway Faculty of Medicine, University of Oslo, Oslo, Norway
    Thromb Res 123:S70-3. 2009
  4. ncbi Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?
    Helene F S Negaard
    J Clin Oncol 24:2683-4; author reply 2684. 2006

Detail Information

Publications4

  1. ncbi Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis
    Anders Dahm
    Department of Hematology, Ulleval University Hospital, Oslo, Norway
    Blood 101:4387-92. 2003
    ..These results indicate that low levels of TFPI, especially low TFPI-free and total antigen in plasma, constitute a risk factor for DVT...
  2. ncbi Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state
    Anders Dahm
    Department of Haematology, Ulleval University Hospital, Oslo, Norway
    Br J Haematol 132:333-8. 2006
    ..9 (1.7-20). We concluded that the effect of hormonal state on dPT was mediated through TFPI, and a dPT-based assay of TFPI anticoagulant activity did not assess the risk for DVT better than conventional TFPI assays...
  3. doi Mechanisms of thrombosis related to hormone therapy
    Per Morten Sandset
    Oslo University Hospital at Ullevål, Department of Hematology, Oslo, Norway Faculty of Medicine, University of Oslo, Oslo, Norway
    Thromb Res 123:S70-3. 2009
    ..Coagulation markers should be used as intermediate or surrogate markers in early pharmacodynamic studies to evaluate the risk associated with new formulations...
  4. ncbi Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?
    Helene F S Negaard
    J Clin Oncol 24:2683-4; author reply 2684. 2006